Unknown

Dataset Information

0

Cardioprotection afforded by inducible nitric oxide synthase gene therapy is mediated by cyclooxygenase-2 via a nuclear factor-kappaB dependent pathway.


ABSTRACT: Gene therapy with inducible nitric oxide synthase (iNOS) markedly reduces myocardial infarct size; this effect is associated with cyclooxygenase-2 (COX-2) upregulation and is ablated by COX-2 inhibitors. However, pharmacological inhibitors are limited by relative lack of specificity; furthermore, the mechanism whereby iNOS gene therapy upregulates COX-2 remains unknown. Accordingly, we used genetically engineered mice to test the hypothesis that the cardioprotection afforded by iNOS gene transfer is mediated by COX-2 upregulation via a nuclear factor (NF)-kappaB-dependent pathway.Mice received an intramyocardial injection of Av3/LacZ (LacZ group) or Av3/iNOS (iNOS group); 3 days later, myocardial infarction was produced by a 30-minute coronary occlusion followed by 4 hours of reperfusion. Among Av3/LacZ-treated mice, infarct size was similar in COX-2(-/-) and wild-type groups. iNOS gene transfer (confirmed by iNOS immunoblotting and activity assays) markedly reduced infarct size in wild-type mice but failed to do so in COX-2(-/-) mice. In transgenic mice with cardiac-specific expression of a dominant-negative mutant of IkappaB alpha (IkappaB alpha(S32A,S36A)), the upregulation of phosphorylated IkappaB alpha, activation of NF-kappaB, and cardiac COX-2 protein expression 3 days after iNOS gene therapy were abrogated, which was associated with the abolishment of the cardioprotective effects afforded by iNOS gene therapy.These data provide strong genetic evidence that COX-2 is an obligatory downstream effector of iNOS-dependent cardioprotection and that NF-kappaB is a critical link between iNOS and COX-2. Thus, iNOS imparts its protective effects, at least in part, by recruiting NF-kappaB, leading to COX-2 upregulation. However, COX-2 does not play an important cardioprotective role under basal conditions (when iNOS is not upregulated).

SUBMITTER: Li Q 

PROVIDER: S-EPMC3654387 | biostudies-literature | 2007 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Cardioprotection afforded by inducible nitric oxide synthase gene therapy is mediated by cyclooxygenase-2 via a nuclear factor-kappaB dependent pathway.

Li Qianhong Q   Guo Yiru Y   Tan Wei W   Ou Qinghui Q   Wu Wen-Jian WJ   Sturza Diana D   Dawn Buddhadeb B   Hunt Greg G   Cui Chuanjue C   Bolli Roberto R  

Circulation 20070904 14


<h4>Background</h4>Gene therapy with inducible nitric oxide synthase (iNOS) markedly reduces myocardial infarct size; this effect is associated with cyclooxygenase-2 (COX-2) upregulation and is ablated by COX-2 inhibitors. However, pharmacological inhibitors are limited by relative lack of specificity; furthermore, the mechanism whereby iNOS gene therapy upregulates COX-2 remains unknown. Accordingly, we used genetically engineered mice to test the hypothesis that the cardioprotection afforded b  ...[more]

Similar Datasets

| S-EPMC2768612 | biostudies-literature
| S-EPMC2952210 | biostudies-literature
| S-EPMC2552398 | biostudies-literature
| S-EPMC3691689 | biostudies-literature
| S-EPMC1895491 | biostudies-literature
| S-EPMC4712158 | biostudies-literature
| S-EPMC3053078 | biostudies-literature
| S-EPMC6908786 | biostudies-literature
| S-EPMC2782783 | biostudies-literature
| S-EPMC2922252 | biostudies-literature